palivizumab
- Product Name
- palivizumab
- CAS No.
- 188039-54-5
- Chemical Name
- palivizumab
- Synonyms
- Synagis;palivizumab;Synagis|||MEDI 493;Research Grade Palivizumab;Research Grade Palivizumab(DVV02801)
- CBNumber
- CB11386500
- Formula Weight
- 0
- MOL File
- Mol file
palivizumab Property
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Safety
- Hazardous Substances Data
- 188039-54-5(Hazardous Substances Data)
palivizumab Chemical Properties,Usage,Production
Uses
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice[1].
Indications
Palivizumab (Synagis) is a humanized monoclonal antibody directed against the highly conserved A antigenic site of the F protein on the surface of RSV. It contains 95% human and 5% murine antibody sequences and tends to have little immunogenicity in humans. Palivizumab is composed of the human framework region of the IgG-1κ-chain joined to the antigen-binding regions of a mouse monoclonal antibody. Palivizumab neutralizes RSV and inhibits its ability to fuse with host cell membranes. Resistant strains of RSV have been derived in vitro but have not been found in clinical isolates to date.
Clinical Use
Palivizumab is used to prevent serious lower respiratory tract infection due to RSV. It is used only in high-risk children who are younger than 24 months of age and have bronchopulmonary dysplasia or chronic lung disease that required treatment in the previous 6 months. It is also indicated for premature infants (less than 32 weeks’ gestation) until the age of 6 to 12 months. Palivizumab can reduce the incidence of RSV-related hospitalization by approximately half.The safety and efficacy of palivizumab in the treatment of RSV disease have not been established.
Side effects
Serious adverse reactions caused by palivizumab are rare.Mild erythema and pain may occur at the injection site.Although no anaphylactoid reactions have been reported to date, the possibility of this reaction exists because palivizumab is a protein.
in vivo
Palivizumab (0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.); single dose) can prevent respiratory syncytial virus infection in cotton mice[1]. Palivizumab (0.05 mg/kg; single dose; intranasally administered)can prevent RSV infection in mice[2]. Palivizumab (15 mg/kg; single dose; s.c.) can inhibit RSV induced airway neurogenic inflammation in rats[3].
| Animal Model: | The cotton rat model of RSV infection[1]. |
| Dosage: | 0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.) |
| Administration: | Intramuscular injection (i.m.) or intravenous injection (i.v.); single dose |
| Result: | Reduced virus replication and did not cause RSV infection or pathological increase in both initial and secondary attacks. |
| Animal Model: | BALB/c mice[2]. |
| Dosage: | 0.05 mg/kg |
| Administration: | Intranasally administered; single dose |
| Result: | Reduced the RSV load. |
| Animal Model: | Capsaicin-induced neurogenic inflammation in the airways of rats[3]. |
| Dosage: | 15 mg/kg |
| Administration: | Subcutaneous injection (s.c.); single dose |
| Result: | Reduced neurogenic extravasation and neurogenic inflammation. |
References
[1] Johnson S, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24. DOI:10.1086/514115
[2] Jacobino SR, et al. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. MAbs. 2018 Apr;10(3):453-462. DOI:10.1080/19420862.2018.1433974
[3] Piedimonte G, et al. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res. 2000 Mar;47(3):351-6. DOI:10.1203/00006450-200003000-00011
palivizumab Preparation Products And Raw materials
Raw materials
Preparation Products
palivizumab Suppliers
- Tel
- 1-(800)-881-8210
- Fax
- 615-250-9817
- inquiries@lgmpharma.com
- Country
- United States
- ProdList
- 2123
- Advantage
- 70
- Tel
- 27-027-83314682 13554138826
- Fax
- +86 (27) 8331-4682
- whsrtech@vip.163.com
- Country
- China
- ProdList
- 246
- Advantage
- 62
- Tel
- 010-56205725
- Fax
- 010-65763397
- waley188@sohu.com
- Country
- China
- ProdList
- 12335
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-59101668 19945030958
- Fax
- 027-59101668
- 2881924765@qq.com
- Country
- China
- ProdList
- 7938
- Advantage
- 58